1-Boc-4- (4-Bromopyrazol-1-yl) piperidine CAS 877399-50-3 Ịdị ọcha ≥98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd bụ onye na-emepụta 1-Boc-4- (4-Bromopyrazol-1-yl) piperidine (CAS: 877399-50-3) nwere àgwà dị elu, etiti nke Crizotinib (CAS: 877399- 52-5).Ruifu Chemical nwere ike ịnye nnyefe zuru ụwa ọnụ, ọnụahịa asọmpi, ọrụ magburu onwe ya, obere na nnukwu ọnụọgụ dị.Ịzụta Crizotinib Intermediates,Please contact: alvin@ruifuchem.com
| Aha Chemical | 1-Boc-4- (4-Bromopyrazol-1-yl) Piperidine |
| Ụdị okwu | Crizotinib-D;tert-Butyl 4- (4-Bromopyrazol-1-yl) piperidine-1-Carboxylate;4- (4-Bromopyrazol-1-yl) piperidine-1-Carboxylic Acid tert-Butyl Ester;1-tert-Butoxycarbonyl-4- (4-Bromopyrazol-1-yl) piperidine;1- (4-Boc-Piperidino) -4-Bromopyrazole;1-Boc-4- (4-Bromo-1-Pyrazolyl) piperidine;4-Bromo-1- (N-Boc-Piperidin-4-yl) -1H-Pyrazole;tert-butyl 4- (4-Bromo-1H-Pyrazol-1-yl) piperidine-1-Carboxylate;1- (4-Boc-1-Piperidinyl) -4-Bromopyrazole;Crizotinib adịghị ọcha 4 |
| Ọnọdụ Ahịa | Na ngwaahịa, Mmepụta Azụmahịa |
| Nọmba CAS | 877399-50-3 |
| Usoro ihe omimi | C13H20BrN3O2 |
| Ibu molekụla | 330.23 g/mol |
| Ebe Na-agbaze | 77.0 ruo 81.0 ℃ |
| Njupụta | 1.43 |
| Solubility | Soluble na methanol |
| COA & MSDS | Dị |
| Mmalite | Shanghai, China |
| Otu | Ọkara nke Crizotinib (CAS: 877399-52-5) |
| Ụdị | Ruifu Chemical |
| Ihe | Ụkpụrụ nyocha | Nsonaazụ |
| Ọdịdị | Ọcha siri ike | Ọcha siri ike |
| Ebe Na-agbaze | 77.0 ruo 81.0 ℃ | Na-akwado |
| Mmiri nke Karl Fischer | <0.50% | 0.11% |
| Ụzọ ịdị ọcha / nyocha | ≥98.0% (HPLC) | 99.3% |
| 1H NMR Spectrum | Dabara na Ọdịdị | Na-akwado |
| Mass | Dabara na Ọdịdị | Na-akwado |
| Mmechi | A nwalela ngwaahịa a wee kwado nkọwa ndị enyere | |
ngwugwu:Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ.
Ọnọdụ Nchekwa:Debe akpa ahụ nke ọma ma chekwaa n'ebe dị jụụ, kpọrọ nkụ (2 ~ 8 ℃) yana ụlọ nkwakọba ihe nke ọma na-esi na ihe ndị na-adabaghị adaba.Chebe site na ìhè na mmiri mmiri.
Mbupu:Jiri ikuku na-ebuga ụwa niile site na FedEx / DHL Express.Nye nnyefe ngwa ngwa na ntụkwasị obi.
Kedu ka esi azụta?Biko kpọtụrụDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
Ahụmịhe afọ 15?Anyị nwere ihe karịrị 15 afọ nke ahụmahụ na mmepụta na mbupụ nke a dịgasị iche iche nke elu mma pharmaceutical intermediates ma ọ bụ ezi kemịkal.
Isi ahịa?Na-ere ahịa ụlọ, North America, Europe, India, Korea, Japanese, Australia, wdg.
Uru?Ogo kachasị elu, ọnụ ahịa dị ọnụ ala, ọrụ ọkachamara na nkwado teknụzụ, nnyefe ngwa ngwa.
OgoNkwenye?Usoro njikwa mma siri ike.Ngwá ọrụ ọkachamara maka nyocha gụnyere NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, wdg.
Ihe atụ?Ọtụtụ ngwaahịa na-enye ihe nlele efu maka nyocha dị mma, ndị ahịa kwesịrị ịkwụ ụgwọ mbupu.
Nyocha ụlọ ọrụ?Nnabata nyocha ụlọ ọrụ.Biko mee oge oge tupu oge eruo.
MOQ?Enweghị MOQ.A na-anabata obere usoro.
Oge Mbuga ozi? Ọ bụrụ n'ime ngwaahịa, ekwenyere nnyefe ụbọchị atọ.
Ụgbọ njem?Site Express (FedEx, DHL), nke ikuku, site n'oké osimiri.
Akwụkwọ?Mgbe ọrụ ahịa gasịrị: COA, MOA, ROS, MSDS, wdg nwere ike ịnye.
Synthesis omenala?Nwere ike ịnye ọrụ nhazi ahaziri iche ka ọ dabara mkpa nyocha gị nke ọma.
Usoro ịkwụ ụgwọ?A ga-ebu ụzọ ziga akwụkwọ ọnụahịa Proforma mgbe nkwenye nke iwu, kpuchiri ozi ụlọ akụ anyị.Ịkwụ ụgwọ site na T/T (Telex Nyefee), PayPal, Western Union, wdg.
Ihe akara egwu Xn - na-emerụ ahụ
Koodu ihe ize ndụ 22 - na-emerụ ahụ ma eloro ya
1-Boc-4- (4-Bromopyrazol-1-yl) piperidine (CAS: 877399-50-3) na-eji dị ka etiti nke Crizotinib (CAS: 877399-52-5).Crizotinib (aha ahia Xalkori,) bụ ọgwụ na-egbochi ọrịa kansa na-arụ ọrụ dị ka ALK (anaplastic lymphoma kinase) na ROS1 (c-ros oncogene 1) inhibitor, kwadoro maka ọgwụgwọ ụfọdụ carcinoma na-abụghị obere cell (NSCLC) na US. na ụfọdụ mba ndị ọzọ, na na-anwale ụlọ ọgwụ na-anwale nchekwa ya na nrụpụta ọrụ anaplastic nnukwu cell lymphoma, neuroblastoma, na etuto siri ike ndị ọzọ dị elu na ma ndị okenye na ụmụaka.
N'August 2011, United States FDA kwadoro Crizotinib (PF-02341066) maka ọgwụgwọ nke anaplastic lymphoma kinase (ALK) megharịrị ọrịa cancer akpa ume na-abụghị obere cell (NSCLC).Crizotinib bụ dual ATP asọmpi inhibitor nke tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50 = 8 nM) na ALK (cellular IC50 = 20 nM), nke abụọ bụ ihe dị mkpa ezubere maka chemotherapy cancer.Mgbe a nwalere Crizotinib maka selectivity megide ndị ọzọ kinases, a chọpụtara na ọ nwere enzyme IC50's n'ime 100-fold multiples nke c-MET maka 13 nke 120 kinases nwalere.Na nyocha ekwentị, ahụrụ Crizotinib ka ọ na-egbochi RON (recepteur d'origine nantais) kinase na windo nhọrọ nke ugboro iri n'elu c-MET.
